Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for XIAP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XIAP Full-Length & BIR Domain Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. BIR2/BIR3 domains available for selective screening. |
View XIAP Products |
| Gene Delivery | XIAP Promise-ORF / Lentivirus Full-length ORF with FLAG/His tags for stable cell line construction. CMV promoter. |
View XIAP Products |
| Research Antibody | Anti-XIAP Monoclonal Antibody Clone verified for Western Blot, IP, and IHC. Recombinant production. |
View XIAP Products |
| Validator | XIAP siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View XIAP Products |
| Related Target: cIAP1 | cIAP1 (BIRC2) Recombinant Protein Paralog for selectivity screening. BIR3 domain available. |
View cIAP1 Products |
| Related Target: cIAP2 | cIAP2 (BIRC3) Recombinant Protein Paralog for selectivity screening. IAP family counter-screening. |
View cIAP2 Products |
| Related Target: SMAC | SMAC (DIABLO) Protein Natural XIAP antagonist. Positive control for binding assays. |
View SMAC Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BIR Domain Selectivity (BIR2 vs BIR3) | Isolated BIR2 and BIR3 domain proteins (>95% purity) with verified boundaries for structure-guided screening |
| Paralog Selectivity (XIAP vs cIAP1/2) | Human XIAP, cIAP1, cIAP2 ortholog proteins strictly verified by mass spec for counter-screening panels |
| SMAC Mimetic Binding Validation | Wild-type vs W310A mutant XIAP BIR3 domain (SMAC-binding deficient) available as negative controls |
| Cellular Target Engagement | High-titer XIAP Lentivirus for stable overexpression cell lines; siRNA for loss-of-function validation |
| Ubiquitination Assay Controls | Full-length XIAP with intact RING domain for E3 ligase activity assays |
Live XIAP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XIAP therapeutics has shifted dramatically from first-generation pan-IAP antagonists to next-generation selective degraders. As SMAC mimetics like GDC-0152 and LCL161 demonstrated limited monotherapy efficacy, the field is pivoting toward combination regimens with chemotherapy and immune checkpoint inhibitors. The emergence of PROTAC technology (e.g., DT2216) represents a critical inflection point, offering selective XIAP degradation while sparing cIAP1/2 to reduce immune toxicity. Xevinapant (Debio 1143) by Debiopharm is currently the most advanced XIAP-targeting candidate, in Phase III for head and neck squamous cell carcinoma. Future R&D focuses on BIR3-domain selective inhibitors, blood-brain barrier penetrant compounds for glioblastoma, and resistance mutation profiling including clinical mutations such as W310A and V325I.
Key Mutations in XIAP and Their Impact on Drug Development
XIAP mutations are associated with X-linked lymphoproliferative syndrome type 2 (XLP2) and can affect drug sensitivity. Key mutations include:
- W310A (BIR3 domain): Disrupts SMAC binding; used as negative control in binding assays.
- VAR_088127 and VAR_088128 (XLP2; uncertain significance): May alter protein stability or function.
- rs28382721 (VAR_022282): A common variant with unknown impact on drug response.
These mutations underscore the need for mutant panels in preclinical screening and companion diagnostic development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| SMAC Mimetic (Small Molecule) | Roche/Genentech, Novartis, Bayer | Solid Tumors, Hematologic Malignancies | BIR3 Domain Binding (Need high-purity BIR3 proteins with verified SMAC-binding groove) |
| PROTAC Degrader | Dialectic Therapeutics, Arvinas | Refractory Cancers | Ternary Complex Formation (Need full-length XIAP + linker chemistry optimization) |
| Antisense Oligonucleotide | AstraZeneca (historical) | Non-small Cell Lung Cancer | Knockdown Efficiency Validation (Need XIAP-specific antibodies & qPCR standards) |
| Bispecific Peptide | Academic/Preclinical | Glioblastoma | Cell Permeability & Stability (Need cell-based XIAP overexpression systems) |